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Introduction
Substance use and mental ill health constitute a major public 
health burden amongst the population1 and globally a key pol-
icy priority is to reduce illicit and other harmful substance use.2 
Amphetamine-type stimulants (ATS) such as amphetamine, 
methamphetamine and methylenedioxy-methamphetamine 
(MDMA/Ecstasy) are the second most commonly used illicit 
drug worldwide, with an increase in production and use seen in 
recent years.3,4 In 2018 lifetime prevalence of ATS use was esti-
mated at 13.5 million (4.1%) for MDMA, and 11.9 million 
(3.6%) for amphetamines amongst 15 to 64 year olds in 
Europe,5 with an estimated 1 in 11 adults in the UK reporting 
consumption at some point in their lives.5,6 In England and 
Wales, the social and economic cost of illicit drug use, includ-
ing policing, crime and healthcare is £10.7 billion per year.7 
However, the societal impacts are further reaching, with the 
practice of problematic substance use in our communities lead-
ing to increased levels of blood-borne viruses, drug-related 
deaths and drug-driven crime. Mental ill health, domestic 
abuse, offending and bereavement are often associated with 
problematic substance use, impacting upon substance users 
themselves, their children, and other significant individuals.7 
There is evidence of discrepancies in care quality for those with 
co-occurring mental health and substance use disorders, 
highlighting the need for more to be done to reduce this ine-
quality, and support these individuals.8
ATS have sometimes been viewed as recreational or ‘safe’ 
drugs, with users reporting perceived positive effects, such as 
increased sociability, energy, talkativeness and positive mood, 
whilst underestimating and less frequently reporting the nega-
tive social and health effects.9,10 However, ATS use has been 
identified as a risk factor for poor mental health, and even seri-
ous mental illness,11,12 with a range of issues documented 
amongst users, including depression, anxiety and changes in 
mood.13 Heavy or prolonged use of some ATS, such as meth-
amphetamine or novel psychoactive substances (NPS) have 
been noted to impact negatively upon individuals’ physical 
health, mental health and neurological functioning,14 with 
some users experiencing transient or persistent psychotic 
symptoms, agitation and insomnia.11,15-18 Short-term issues 
may be due to the acute effects of ATS intoxication, however 
prolonged effects may be related to withdrawal.1 The relation-
ship between, and co-occurrence of, mental health issues and 
substance use is complex and bi-directional in nature, and both 
may have a common set of underlying and often compounded 
causes located across individual and structural factors.19-21 It 
has also been argued that individuals who experience mental ill 
health problems are more likely to be or become dependent on 
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substances22 and similarly, individuals who misuse substances 
appear to be more likely to develop or suffer from mental 
health problems.23 Determining whether the mental health 
issue or problematic substance use occurred first is further 
complicated because the relationship between psychological 
symptoms and substance use is temporal, meaning that many 
individuals may experience both substance-induced and sub-
stance-independent mental health issues throughout the course 
of their substance use careers.24,25 Despite existing research 
having established a link between ATS use and mental health 
issues, there is little known about the order of onset and the 
implications of this for treatment.26,27
The mixed-methods European ‘ATTUNE’ study aimed 
to address a gap in knowledge on what shapes ATS use across 
the life-course; how to prevent and treat harmful ATS use 
and what influences different trajectories of consumption 
through individuals’ lives. Prior to this, there was limited 
understanding around which factors lead to increased ATS 
use, or what could help to facilitate decreased use, or desist-
ance.28,29 This paper reports on a sub-sample of ATTUNE 
qualitative data collected from interview participants in the 
North East of England, and aims to specifically explore indi-
vidual experiences of, and perspectives on the relationship 
between mental health and ATS consumption. This is 
important, as there has been little investigation of the rela-
tionship between ATS use and co-occurring mental health 
problems,30 the management of which continues to be chal-
lenging for clinicians.31 There is not yet an established sub-
stitute pharmacological treatment for dependent ATS 
users.32 Whilst some considerable psychological and psycho-
social intervention developments have been made in recent 
years,33,34 treatment services are predominantly based on a 
medical model, geared towards alcohol and opioid depend-
encies, which ignores the social and environmental drivers of 
substance use, and characterises people who use substances 
as requiring external control.35
Methods
Design
Qualitative research is recognised as enabling in-depth analysis 
of socially situated experiences, and can help to provide insight 
into otherwise unknown practices; ensuring better-informed 
public health policy decisions through the identification of 
optimal opportunities for intervention, prevention and treat-
ment.36 The qualitative phase of the ATTUNE study used in-
depth semi-structured interviews with ATS users and 
non-users, to provide an in-depth understanding of the lived 
experiences of participants and the factors which shape differ-
ent trajectories of ATS use through the life-course. Ethical 
approval was granted by Newcastle University, Faculty of 
Medical Sciences, Ethics Committee (REF: 01204/2016) on 
8th September 2016. Interviews were conducted between 
February and July 2017.
Recruitment and sample
Interviews were conducted in the North East of England, a 
region that has experienced substantial economic decline since 
the 1980s, with high levels of unemployment, disability and 
economic inactivity.37,38 To be eligible to participate, individu-
als must: have first used, or had the opportunity to use ATS at 
least 5 years previously; be over 18 years of age; have lived in the 
North East of England and have appropriate verbal and cogni-
tive skills to provide informed consent. Relevant organisations, 
such as homeless charities, substance use services and proba-
tion teams across the North East region signposted potentially 
eligible participants to study information. Flyers and posters 
advertising the study were distributed amongst local commu-
nity spaces, including cafes, bars and libraries. The study was 
also advertised online, through social media and via national 
academic, policy and practice community networks. ATS use 
was categorised as current (use within the past 12 months) and 
former (use over 12 months ago). Users were further catego-
rised according to whether they were: current/former depend-
ent users (positive [⩾4] Severity of Dependence Scale39 [SDS] 
score); current/former frequent users (at least 10 days use, but 
not SDS positive); or current/former non-frequent users (less 
than 10 days use in a 12 month period).28,40
Data collection
Potential participants were provided with an information leaflet, 
explaining that their participation was confidential and anony-
mous, and were given the opportunity to ask any questions. If the 
individual was willing, able and eligible to participate, then writ-
ten informed consent was obtained. The interviews were con-
ducted face-to-face by 1 of 3 members of the research team 
(MA, LS, WM). A semi-structured interview topic guide was 
used, with questions and follow-up probes related to family, 
physical and mental health and key turning points in drug use 
trajectories, namely initiation, continuation, decrease, desistance 
and relapse of ATS use. The interviews were digitally audio-
recorded and transcribed verbatim. We continued data collection 
until there was maximum diversity across the sample in terms of 
ATS use, age, gender and socioeconomic status41; and data satu-
ration was believed to have been achieved, as identified through 
repetition of responses and sufficient data to answer the research 
questions.42 Participants received a £10 shopping voucher incen-
tive for participating. Interviews lasted between 18 and 106 min-
utes (mean = 48 minutes).
Analysis
During an initial framework analysis43 of the whole sample of 
n = 70 interviews, a sub-sample of n = 18 current and former ATS 
users were identified. The relationship between mental health 
and ATS consumption was already an identified knowledge gap 
in this area,30-32,35 therefore further analysis was conducted using 
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a thematic approach44 by LS, to focus specifically on this issue. It 
is however important to note that this does not mean that the 
remainder of the whole sample experienced no mental health 
challenges, just that the focus here was on those for whom these 
challenges were a recurrent theme and central issue. Data were 
coded iteratively, using a combination of inductive and deductive 
approaches and emergent themes were discussed with AOD and 
HA. Bronfenbrenner’s ecological theory was drawn upon in 
order to help better understand and unpack patterns and risk 
factors associated with co-occurring substance use and mental 
health.45 This theory was used to guide the interpretation of 
data; and states that individuals are shaped not only by individual 
factors, but to a great extent by the social, economic and physical 
environments in which they are situated.44 Considering interac-
tions within and between these different ecological systems 
offers a way to focus on both intrapersonal and environmental 
factors, and the dynamic interplay between these factors in 
determining behaviours and health outcomes,46,47 which was 
useful to consider whilst exploring the complex issue of interest. 
All data were coded and organised using NVivo 11.
Findings
The 18 current and former ATS users interviewed were aged 
20 to 45 (mean age = 33.2 years; 56% male, 44% female). The 
characteristics of the participants are presented in Table 1. The 
findings are categorised in relation to 3 key turning points in 
ATS use careers: (1) initiation; (2) continued and/or increased 
use and (3) decreased and/or remitted use, exploring the inter-
action between mental health and ATS use at each turning 
point. Each category is presented in greater detail below, with 
verbatim quotations to illustrate the findings.
Initiation of ATS use
Participants discussed the initiation of ATS use with reference 
to a variety of factors, both in terms of strategies to promote or 
improve positive mental health and wellbeing, as well as func-
tional or preventative strategies to cope with or prevent further 
deterioration of existing mental health issues. For many indi-
viduals, a combination of these were evident, and experiencing 
co-occurring stressors and chaotic life circumstances further 
compounded their ability to cope.
A perceived mental health promoting benefit of ATS was 
improved alertness and increased energy levels, which partici-
pants believed allowed them to function better, and to negoti-
ate the demands of their day-to-day lives. Many participants 
experienced multiple stressors in their lives, and this was one of 
the main contributing factors in their initiation of ATS use. 
They normalised their use as a way of as managing childcare 
(particularly mothers), and employment.
‘I was managing work, full-time employment, with football, with 
two children’. (36-year-old male, former dependent user)
‘I was getting up during the night to feed (the baby) and stuff like 
that. Then his dad came in one day and he had something, and I 
just took it’. (30-year-old female, former dependent user)
Some participants also spoke about experiencing low self-
esteem and a lack of confidence, therefore turning to ATS use 
to boost their self-belief, and navigation of social situations. 
They believed that using ATS improved self-concept, and for-
tified personality traits which they had previously perceived as 
fragile, making them feel more extraverted, presenting fewer 
neurotic symptoms and therefore better positioned to cope in 
their day-to-day lives.
‘The drugs did for me what I couldn’t do for myself. They made me 
confident. They made me talkative, especially drugs like Ecstasy’. 
(38-year-old male, former dependent user)
‘It was quite good for confidence at first, it’s not until later on you 
realise what it does’. (40-year-old male, current dependent user)
Participants also reported that ATS provided them with an 
opportunity to escape problems they faced in their lives, which 
were causing significant distress, when they felt that it was not 
possible to overcome these issues or find solutions to improve 
their situation. These concerns included strained relationships 
with partners and family members, financial worries, as well as 
issues associated with existing mental ill health. Many 
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participants spoke about being offered ATS from concerned 
others, such as friends and family members, who suggested it as 
an alternative way of coping with the chaotic facets of their lives.
‘I heard people take drugs just to escape from the arguing. That’s 
what I wanted at first, so I started taking it like that’. (40-year-old 
male, current dependent user)
‘Folk take it to hide their feelings, to cover up stuff, just to make 
themselves feel better because when you’re on drugs, you’re on top 
of the world. Nothing can hurt you; you feel invincible’. (21-year-
old female, current dependent user)
Participants referred to the impact of particularly traumatic 
events in their lives, and how ATS use was something they 
engaged with to cope with the emotional distress they felt. 
Many of these traumatic events had occurred recently, such as 
the dissolution of a romantic or intimate relationship, or 
bereavement from the loss of a partner or family member. 
However, participants also referred to the lasting impact of 
adverse events which had occurred in the past (including 
adverse childhood experiences), such as traumatic childhood 
events and historic sexual abuse, and how ATS use lessened the 
impact of these painful memories on their present-day lives.
‘When our relationship completely broke down, he hung himself. 
This was the point where my life spiralled out of control’. (44-year-
old female, former dependent user)
‘I came from obviously a dysfunctional childhood, a dysfunctional 
family. I was in and out of the care system until I was quite old 
actually. That would also give me a release from everything I used 
to think about’. (40-year-old male, current dependent user)
Continued and increased ATS use
When participants discussed factors that encouraged them to 
continue and potentially increase their use of ATS, they referred 
to the continued management of multiple stressors in their 
lives, the perception of apparent positive effects on their mental 
health and wellbeing, and the need to self-manage deleterious 
effects of ATS use.
Many participants highlighted the perceived positive effects on 
their mental health, as a result of using ATS. These included feel-
ing more confident and less anxious, a perceived sense of better life 
management, and feeling they were better equipped to cope with 
their day-to-day circumstances. These individuals continued using 
ATS as an attempt to sustain these desirable effects, which were 
associated with an overall sense of bolstered wellbeing.
‘I felt like I was invincible, honest to God, I could run five Great 
North Runs. It took the weight off my shoulders. It like my prob-
lems had just gone. I got my confidence. I liked it’. (41-year-old 
female, current dependent user)
‘They made me confident. They made me talkative, especially 
drugs like Ecstasy and stuff like that’. (38-year-old male, former 
dependent user)
Several participants also described the ongoing management of 
their ‘chaotic’ lives, the negotiation of multiple individual, social 
and environmental stressors and deteriorating mental health as 
motivation for continued ATS use. As their circumstances 
became increasingly demanding and pressurised, ATS use 
became increasingly normalised and a part of their daily rou-
tine. Over time, most dependent users could not see a way of 
pursuing their lives without using ATS to support them, even 
if their ATS was contributing to their deteriorating mental 
health.
‘I was dealing with the death of my children’s dad, and I think 
because without it I had no energy at all. Looking back now I was 
probably very severely depressed, so I was kind of using it as a cop-
ing mechanism’. (44-year-old female, former dependent user)
‘My mental state just got a bit erratic. I started getting very angry 
once I’d been up for a couple of days, so my head was just a bit all 
over the place’. (23-year-old male, former frequent non-dependent 
user)
A dominant theme was self-management of the ‘comedown’ 
from ATS intoxication. Participants spoke about experiencing 
worsening psychological symptoms, including low-mood, anx-
iety, feelings of paranoia, engaging in self-harm behaviours and 
experiencing thoughts of suicide. This deterioration in mental 
health led to continued and/or increased ATS use to ‘self-med-
icate’ these symptoms, even though these issues were often, but 
not exclusively, their reason for initiating ATS use to begin 
with. Some participants reported that as their use continued, 
these symptoms worsened even further, leading them to 
increase their consumption use both in terms of frequency and 
quantity, establishing a cycle of maladaptive ATS use 
behaviour.
‘On a come down and you’re like, fuck my life. Genuinely, that’s 
what it’s like and then you feel sorry for yourself again for like two 
days, three days and then you’re fine. Then before you know it, 
again, another one’s been ordered’. (21-year-old female, current 
dependent user)
‘I’ve used various things in between that, but I always went back to 
amphetamines. It’s the only thing that’s kept us normal. I’m para-
noid when I’m not in it, but when I have it, it takes away the para-
noia’. (40-year-old male, current dependent user)
Decreased and remitted ATS use
Participants discussed the negative impacts of continued ATS 
use, such as a decline in overall mental health functioning, and 
negative changes to their personality as motivating factors in 
reducing or ceasing their ATS use. Participants also referred to 
a desire for change and wanting a ‘better life’. ATS users who 
had managed to reduce or cease their use spoke about the res-
toration of ‘normality’ in their lives.
Many participants had previously referred to perceived pos-
itive impacts on their wellbeing due to ATS use, including 
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increased confidence. However, after prolonged use several 
participants described becoming increasingly aware of negative 
traits and changes to their personas, including paranoia, which 
they attributed to their ATS use. These perceived changes in 
personality often motivated a desire to reduce or cease ATS 
use.
‘Your personality can flip side, you know, popular, sociable, outgo-
ing person and then you’re going to lose the grip on who you are’. 
(40-year-old male, former non-frequent user)
‘I changed in the sense of the drugs I as taking. I wasn’t the nice 
fella. I became very controlling, very paranoid, really insecure’. 
(38-year-old male, former dependent user)
Despite many participants describing that they initially experi-
enced an alleviation of their negative mental health symptoms 
from using ATS, after prolonged use these perceived benefits 
very often became less pronounced, or harder for the user to 
identify. For those users who reported increasing or uncon-
trolled use, participants became more focussed on their sub-
stance use as a way of alleviating symptoms of mental ill health. 
Many participants described deleterious impacts on their men-
tal health functioning, as their use increased in terms of both 
frequency and quantity. This was often cited as a motivating 
factor in reducing or stopping the use of ATS. However, it was 
often not until participants reached a point of crisis which 
resulted in the intervention of support services, before reduced 
ATS use occurred.
‘I was dead August last year, everything, and no feelings, nothing, 
soul gone, the lot. You know, it was just black dog’. (40-year-old 
male, former non-frequent user)
‘I was suicidal. I wanted to die. I didn’t want to live, and I hated 
myself, all that self-loathing and stuff and self-hatred. I thought 
everybody hated me’. (38-year-old male, former dependent user)
Many participants spoke about a breaking point or hitting ‘rock 
bottom’ as a primary motivating factor in the decision to mod-
ify their ATS use. By this stage, participants were unable to 
associate their ATS use with any benefits or positive effects, 
and instead apportioned the blame for their negative mental 
health state and the poor circumstances of their lives to their 
ATS use. This motivated a desire for change and wanting a 
‘better life’.
‘It got to a point where I thought, “I’ve got to sort my head out,” 
because I’d gotten myself into a bit of a rut’. (40-year-old male, 
former dependent user)
‘For me it was 25, which I’m really grateful for that I hit that rock 
bottom and I realised I’d had enough because I did’. (38-year-old 
male, former dependent user)
However, for many participants change was an incremental 
process, and relapse was a common occurrence for participants, 
with the overall reduction and desistence from use very much 
associated with building personal resilience over time. 
Individual, social and environmental triggers often provided 
the catalyst for relapse and re-engagement with ATS use, fol-
lowed by a period of reflection and consolidation of goals by 
the individual user. Participants who had successfully been able 
to reduce their ATS use, or stop all together, spoke about the 
restoration of a positive state of mental health and emotional 
wellbeing; being able to engage in positive everyday activities, 
which had not been possible amid their most intensive phase of 
ATS use. Participants were able to re-establish ‘normal’ prac-
tices, such as maintaining a regular sleeping pattern, getting up 
out of bed and ready and leaving the house, which individuals 
has previously struggled to sustain. This restoration of normal-
ity was perceived as a hugely important step forward in partici-
pants’ recovery.
‘I can smile. I can brush my hair, put a bit of make-up on. I walked 
up here. I am going to bed at nine, ten o’clock on a night and I am 
sleeping all night. Usually, I wouldn’t be able to sleep until three, 
four o’clock in the morning’. (29-year-old female, former frequent 
non-dependent user)
‘Basically, I’ve resurrected my own mind, body and soul and it took 
me three and a half months’. (40-year-old male, former non-fre-
quent user)
Discussion
We found that the initiation of ATS use was often initially 
viewed by participants as a positive strategy for bolstering their 
wellbeing and confidence, or as a coping mechanism for man-
aging poor mental health and escaping traumatic or challeng-
ing issues. Continuation and increase of ATS use were 
associated with the continued management of multiple stress-
ors in their lives; positive perception of effects on their wellbe-
ing; management of negative side effects and self-medicating 
to maintain the perceived mental health benefits. Reducing 
and ceasing ATS use were associated with a decline in overall 
mental health functioning; negative personality changes; and a 
desire for change and wanting a ‘better life’. Participants 
referred to the lasting impact of events which had occurred in 
the past, and existing research has suggested that experiences of 
trauma may be an important risk factor for distinguishing indi-
viduals who develop substance use issues, from those who do 
not.48,49 This follows existing research that states that age and 
stage of life may play an important part in determining whether 
or not individuals are able to use adaptive coping strategies, 
with users who initiate substance use at an earlier age display-
ing higher disengagement, lesser use of social support, higher 
problem avoidance and increased social withdrawal.50,51 
Participants discussed a range of short-term and prolonged 
effects on their mental health, including depression and anxiety 
disorders, which have previously been documented amongst 
ATS users, related both to the acute effects of intoxication and 
prolonged effects related to withdrawal.1,13
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Continued use was perpetuated by the perceived positive 
influences using ATS was having on individuals’ lives. However, 
increased ATS use was also associated with the requirement for 
greater amounts of ATS to elicit similar effects, or to counter 
negative side effects and ‘come-downs’. Self-medication was 
initially perceived as beneficial, and there is existing evidence 
that some users engage in ATS use as a form of self-medication 
for existing mental ill-health, or to manage symptoms associ-
ated with ADHD.52 However, many individuals reported their 
mental health issues worsening due to prolonged ATS use, and 
often found these effects to be outweighing the positives over 
time. Participants also referred to adverse changes in their per-
sonality with prolonged ATS use, and factors associated with 
personality type, and the presence of certain personality disor-
ders could provide explanation for increased risk of poor men-
tal health outcomes, and substance use dependency.53,54
A desire for a ‘better life’ or ‘normality’ was one of the 
strongest motivating factors for participants to stop using ATS, 
and much existing research has focussed on early adulthood as 
the period when regular and heavy use of substances declines; 
due to abundant social role transitions during this period, a 
process known as ‘maturing out’.55 However, for some users, it 
is only when a point of crisis is reached, which serves as a turn-
ing point and that there is an opportunity for individuals to 
break the cycle of substance use and seek support or treat-
ment.56,57 The social identity model of recovery proposes that 
these turning points can constitute the beginning of a process 
that allows individuals to construct an identity that supports 
their transition to recovery.58 However, by this definition there 
is a risk for some users that a reduction in ATS use may not 
occur without a ‘crisis’, which could have other far-reaching 
impacts on their lives.
In society, ATS are often perceived as safe and recreational 
substances,9 which is a major barrier to the prevention and 
treatment of problematic use, and to effective public health 
messaging, which in recent decades has focussed on harm 
reduction,59 rather than scare tactics and fear-based messages, 
which whilst often drawing criticism, may be effective preven-
tion strategies.60 This, in association with medical models 
which characterise addition as a primary chronic disease of 
neural circuitry,35 focussing on medical solutions to social 
problems,61,62 and a lack of targetted treatment for problematic 
ATS use, continues to leave affected individuals at disadvan-
tage.32 Another concept which may influence help-seeking, 
and the remittance of ATS use is ‘flourishing’, which proposes 
that high levels of both hedonic well-being (life-satisfaction, 
happiness) and eudaimonic well-being (social contribution, 
purpose in life, personal growth) reduces the risk of mental 
health and substance use disorders, but only when taking into 
consideration the impact of life-events and social support.63 
This is particularly relevant here, as existing research has shown 
that dependent ATS users experience a greater number of neg-
ative life events, and that individuals’ social environment is 
affected by these negative life events.64
This work helps to develop understanding around the com-
plex and bi-directional relationship between ATS use and 
mental health,19-21 and importantly highlights that individuals 
change their use of substances throughout their drug use 
careers as both antecedents to and consequences of their men-
tal health. The findings from this study highlight that there is 
no ‘one size fits all’ approach to prevention and treatment, and 
rather than focussing on whether it is the mental health or sub-
stance use issue which occurred first, it is important to focus on 
users’ individual circumstances and work to address these issues 
in co-occurrence.24,65
Strengths and limitations
The principle strength of this work is the qualitative nature of 
enquiry, which responds to a growing momentum and commit-
ment to include the experiences and views of those whose voices 
are often overlooked or under-represented.66 These findings help 
to challenge stereotypes about substance use, develop a deeper 
understanding of hidden populations and behaviours, and further 
demonstrate that substance use is shaped by a complex set of 
individual, social, environmental and cultural factors.29,36 Whilst 
the sub-sample was relatively small, it was diverse in terms of age, 
gender and current or former ATS use status, and recruitment 
was undertaken via multiple sources, which allowed individuals 
from a variety of backgrounds to engage with the research and 
provide rich accounts of their experiences. The ATTUNE study 
only collected data in the North East of England, an area which 
has its own cultural dynamics, and economic challenges37,38,67; 
with a higher rate of drug-related deaths (96.3 per million peo-
ple) than any other region in England or Wales68,69; the highest 
suicide rate in England,70 and low levels of ethnic diversity,71 
which may not make the findings generalisable to other regional 
contexts, or countries. Whilst we attempted recruitment via 
organisations representing lesbian, gay, bisexual, transgender, 
queer/questioning and intersex (LGBTQI) communities, we had 
no success; and additionally, sexuality and gender identity infor-
mation about participants was not collected. This is a further 
limitation of the study, as we know that gay and bisexual men use 
illicit drugs, including ATS, at higher rates than most other pop-
ulation groups.72,73
Conclusions
Many ATS users lead chaotic lives and engage in multiple risk 
behaviours, however there is a need to better understand and 
conceptualise the dynamic interaction between different indi-
vidual, social, environment and cultural factors that determine 
individuals’ mental health and substance use trajectories, as they 
are not a homogenous group.45-47 The early identification of 
issues associated with both mental health and ATS use is uni-
versally important, to ensure they do not perpetuate one another, 
and these findings highlight the need for more joined-up, tai-
lored and holistic approaches to intervention development. A 
public health approach could be through preventative work in 
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schools, particularly focussing on misconceptions about the 
safety of ATS; the relationship between mental health and sub-
stance use and reducing stigmatisation. Policymakers must also 
remain mindful that the prevalence of both ATS and mental 
health issues are higher in more deprived areas, and therefore 
preventative strategies should be targetted at these areas accord-
ingly. Future research should also engage with varied and diverse 
population groups; and explore in-depth individuals’ prefer-
ences for, and acceptability of treatment opportunities, and the 
barriers and facilitators to accessing treatment.
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